Identifying colorectal cancer subtypes could lead to improved treatment decisions

Identifying a metastatic colorectal cancer patient’s Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. For example, Survival for CMS1 patients on bevacizumab was twice that of those on cetuximab, whereas survival for CMS2 patients on cetuximab was six months longer than for bevacizumab.

Quelle: Sciencedaily